HIV vaccines

Infectious Disease Clinics of North America

Volumn 13, Issue 1, 1999, Pages 95-112

  Frey, S E ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

DRUG SAFETY; ETHICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW; SOCIAL ASPECT;

EID: 0032935899     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70045-3     Document Type: Article

References (162)

1. AIDS Action Foundation Working Group HIV Preventative Vaccines: Social, Ethical, and Political Considerations for Domestic Efficacy Trials 1994 Office of AIDS Research, National Institutes of Health Washington, DC
2. AIDS Vaccine Advocacy Coalition: 9 years and counting. Will we have an HIV vaccine by 2007? An agenda for action for an HIV Vaccine by the AIDS Vaccine Advocacy Coalition, May, 1988
3. M. Alizon P. Sonigo F. Barre-Sinoussi Molecular cloning of lymphadenopathy-associated virus Nature 312 1984 757
4. R.M. Anderson J. Swinton G.P. Garnett Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection Proc R Soc Lond B Biol Sci 261 1995 147
5. S. André B. Seed J. Eberle Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage J Virol 72 1998 1497
6. Arthur L.O. Bess J.W. Jr R.C. Sowder Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines Science 258 1992 1935
7. T.W. Baba Y.S. Jeong D. Penninck Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques Science 267 1995 1820
8. M.E. Bachmann E.L. Delwart E.G. Shpaer Rapid genetic characterization of HIV type 1 strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay AIDS Res Hum Retroviruses 10 1994 1345
9. D. Baltimore Lessons from people with nonprogressive HIV infection N Engl J Med 332 1995 259
10. T. Barnett P. Blaikie Aids in Africa: Its Present and Future Impact 1992 Bellhaven Press London
11. R.B. Belshe M.L. Clements R. Dolin Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection J Infect Dis 168 1993 1387
12. R.B. Belshe K.S. Graham M.C. Keefer Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network JAMA 272 1994 475
13. M. Bendinelli M. Pistello S. Lombardi Feline immunodeficiency virus: An interesting model for AIDS studies and an important cat pathogen Clin Microbiol Rev 8 1995 87
14. P.W. Berman A.M. Gray T. Wrin Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers J Infect Dis 176 1997 384
15. P.W. Berman K.K. Murthy T. Wrin Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate from human immunodeficiency virus type 1 J Infect Dis 173 1996 52
16. B.B. Bloom The highest attainable standard: Ethical issues in AIDS vaccines Science 279 1998 186
17. D. Bolognesi Human immunodeficiency virus vaccines Anonymous Advances in Virus Research 1993 Academic Press San Diego 42
18. S. Broder R.C. Gallo A pathogenic retrovirus (HTLV-III) linked to AIDS N Engl J Med 311 1984 1292
19. P.A. Broliden K. Ljunggren J. Hinkula A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization J Virol 64 1990 936
20. M. Carlesimo O. Pontesilli E.C. Guerra Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) env glycoprotein in HIV-1 infected persons J Infect Dis 176 1997 904
21. Centers for Disease Control and Prevention Heterosexually acquired AIDS—United States, 1993 MMWR 43 1994 155
22. Centers for Disease Control and Prevention HIV testing among women aged 18–44 years—United States, 1991 and 1993 MMWR 45 1996 733
23. Centers for Disease Control and Prevention Kaposi's sarcoma and Pneumocystis pneumonia—New York City and Los Angeles MMWR 30 1981 305
24. Centers for Disease Control and Prevention Pneumocystis pneumonia MMWR 30 1981 250
25. Centers for Disease Control and Prevention Update: Mortality attributable to HIV infection among persons aged 25–44 years—United States, 1991 and 1992 MMWR 42 1993 869
26. Centers for Disease Control and Prevention Update: Mortality attributable to HIV infection among persons aged 25–44 years—United States, 1994 MMWR 45 1996 121
27. R. Cheingsong-Popova S. Lister D. Callow Serotyping HIV type 1 by antibody binding to the V3 loop: Relationship to viral genotype AIDS Res Hum Retroviruses 10 1994 1379
28. K. Cichutek Nucleic acid immunization: A prophylactic gene therapy? Vaccine 12 1994 1520
29. M.L. Clements-Mann D.K. Weinhold T.J. Matthews Immune responses to human immunodeficiency virus (HIV) type 1 induced by Canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults J Infect Dis 177 1998 1230
30. M. Clerici Cell-mediated immunity in HIV infection AIDS 7 suppl 1 1993 S135
31. J. Cohen AIDS research shifts to immunity Science 257 1992 152
32. J. Cohen Looking for leads in HIV's battle with immune system Science 276 1997 1196
33. J. Cohen A new goal: Preventing disease, not infection Science 262 1993 1820
34. J. Cohen Thailand weighs AIDS vaccine tests Science 270 1995 904
35. E. Connor R.S. Sperling R. Gelber Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 331 1994 1173
36. R.I. Connor B.T.M. Korber B.S. Graham Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines J Virol 72 1998 1552
37. E.L. Cooney A.C. Collier P.D. Greenberg Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein Lancet 337 1991 567
38. L. Corey J. McElrath K. Weinhold Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen J Infect Dis 177 1998 301
39. A.G. Dalgleish C.L. Beverly P.R. Clapham The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312 1984 763
40. M.D. Daniel F. Kirchhoff S.C. Czajak Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene Science 258 1992 1938
41. R.C. Desrosiers HIV with multiple gene deletions as a live attenuated vaccine for AIDS AIDS Res Hum Retroviruses 8 1992 411
42. R.C. Desrosiers M.S. Wyand T. Kodama Vaccine protection against simian immunodeficiency virus infection Proc Natl Acad Sci U S A 86 1989 6353
43. de Vries P. J.L. Heeney J. Boes Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines Vaccine 12 1994 1443
44. D.O. Dixon W.N. Rida P.E. Fast HIV vaccine trials: Some design issues including sample size calculations J Acquir Immune Defic Syndr Hum Retrovirol 6 1993 485
45. R. Dolin S. Barney B.S. Graham The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans Ann Intern Med 114 1991 119
46. J.J. Donnelly J.B. Ulmer M.A. Liu Immunization with polynucleotides: A novel approach to vaccination Immunologist 2 1994 20
47. P.J. Easterbrook Non-progression in HIV infection AIDS 8 1994 1179
48. N. El-Daher M.C. Keefer R.C. Reichman Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines J Infect Dis 168 1993 306
49. J. Embretson M. Zupancic J.L. Ribas Massive cohort infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS Nature 362 1993 359
50. A.M. Eroshkin E.A. Karginova I.P. Gileva Design of four-helix bundle protein as a candidate for HIV vaccine Protein Eng 8 1995 167
51. J. Esparza Development of WHO-sponsored sites for HIV vaccine evaluation AIDS Res Hum Retroviruses 9 suppl 1 1993 S133
52. J. Esparza S. Osmanov The development and evaluation of HIV vaccines Curr Opin Infect Dis 6 1993 218
53. J. Esparza S. Osmanov W. Heyward Ethical aspects of trials of candidate vaccines against the human immunodeficiency virus (HIV) Collection Foundation Marcel Merieux 330 1994
54. J. Esparza S. Osmanov L.O. Kallings Planning for HIV vaccine trials: The World Health Organization perspective AIDS 5 suppl 2 1991 S159
55. P.E. Fast B.J. Mathieson A.M. Schultz Efficacy trials of AIDS vaccines: How science can inform ethics Curr Opin Immunol 6 1994 691
56. P.E. Fast C.M. Walker Human trials of experimental AIDS vaccine AIDS 7 suppl 1 1993 S147
57. A.S. Fauci The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis Science 239 1988 617
58. B. Fleury G. Janvier G. Pialoux Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160 J Infect Dis 174 1996 734
59. P.N. Fultz Nonhuman primate models for AIDS Clin Infect Dis 17 suppl 1 1993 S230
60. P.N. Fultz P. Nara F. Barre-Sinoussi Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells Science 256 1992 1687
61. E.F. Fynan R.G. Webster D.H. Fuller DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations Proc Natl Acad Sci U S A 90 1993 11478
62. R.C. Gallo S.Z. Salahuddin M. Popovic Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS Science 224 1984 500
63. F. Gao L. Yue S. Craig Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: Generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO network for HIV isolation and characterization AIDS Res Hum Retroviruses 10 1994 1359
64. L.D. Giavendoni V. Planelles N.L. Haigwood Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection J Virol 67 1993 577
65. M. Girard The needs and hopes for an AIDS vaccine Biochimie 75 1993 583
66. M.P. Girard M.P. Kiery A. Pinter Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus infection Proc Natl Acad Sci U S A 88 1991 542
67. G.J. Gorse M.C. Keefer R.B. Belshe A dose-ranging study of a prototype synthetic HIV-1MNV3 branched peptide vaccine J Infect Dis 173 1996 330
68. G.J. Gorse M.J. McElrath T.J. Matthews Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration Vaccine 16 1998 493
69. G.J. Gorse H. Schwartz B.S. Graham HIV-1 recombinant gp160 vaccine given in accelerated dose schedules Clin Exp Immunol 98 1994 178
70. B.S. Graham Serological responses to candidate AIDS vaccines AIDS Res Hum Retroviruses 10 suppl 2 1994 S145
71. B.S. Graham R.B. Belshe M.L. Clements Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial J Infect Dis 166 1992 244
72. B.S. Graham G.J. Gorse D.H. Schwartz Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus J Infect Dis 170 1994 782
73. B.S. Graham M.C. Keefer M.J. McElrath Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120 Ann Intern Med 125 1996 270
74. B.S. Graham T.J. Matthews R.B. Belshe Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults J Infect Dis 167 1993 533
75. B.S. Graham M.J. McElrath R.I. Connor Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines J Infect Dis 177 1998 310
76. A. Granelli-Piperno E. Delgado V. Finkel Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells J Virol 72 1998 2733
77. W.C. Greene The molecular biology of human immunodeficiency virus type 1 infection N Engl J Med 324 1991 308
78. J.C. Griffiths F.L. Berrie L.N. Holdsworth Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant J Virol 65 1991 450
79. J.C. Griffiths S.J. Harris G.T. Layton Hybrid human immunodeficiency virus gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a gag: V3 fusion J Virol 67 1993 3191
80. L.G. Gürtler P.H. Hauser J. Eberle A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon J Virol 68 1994 1581
81. B.F. Haynes Scientific and social issues of human immunodeficiency virus vaccine development Science 260 1993 1279
82. D.D. Ho J.A. McKeating X.L. Li Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody J Virol 65 1991 489
83. D.D. Ho A.U. Neumann A.S. Perelson Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123
84. S.L. Hu K. Abrams G.N. Barber Protection of macaques against SIV by subunit vaccines of SIV envelope glycoprotein gp160 Science 255 1992 456
85. S.L. Hu P.N. Fultz H.M. McClure Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees Nature 328 1987 721
86. Y. Huang L. Zhang D.D. Ho Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection J Virol 69 1995 93
87. Z.R. Israel P.F. Edmonson D.H. Maul Incomplete protection, but not suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines J Virol 68 1994 1843
88. K. Javaherian A.J. Langlois G.J. LaRosa Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 Science 250 1990 1590
89. K. Javaherian A.J. Langlois C. McDanal Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein Proc Natl Acad Sci U S A 86 1989 6768
90. J.O. Kahn K.S. Steimer J. Baenziger Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 patient in a volunteer in an HIV-1 vaccine clinical trial J Infect Dis 171 1995 343
91. J.M. Karon J.W. Buehler R.H. Byers Projections of the number of persons diagnosed with AIDS and the number of immunosuppressed HIV-infected persons— United States, 1992–1994 MMWR 41 1992 1
92. D.T. Karzon D.P. Bolognesi W.C. Koff Development of a vaccine for the prevention of AIDS, a critical appraisal Vaccine 10 1992 1039
93. M.C. Keefer M. Wolff G.J. Gorse Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS vaccine evaluation group AIDS Res Human Retroviruses 13 1997 1163
94. F. Kirchhoff T.C. Greenough D.B. Brettler Brief Report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection N Engl J Med 32 1995 228
95. W.C. Koff The next steps toward a global AIDS vaccine Science 266 1994 1335
96. B.T.M. Korber S. Osmanov J. Esparza The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature AIDS Res Hum Retroviruses 10 1994 1355
97. R.A. Koup D.D. Ho Shutting down HIV Nature 370 1994 416
98. R.A. Koup J.T. Safrit Y. Cao Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J Virol 68 1994 4650
99. P. Kunasol International HIV/AIDS vaccine trials: Expectations of host countries AIDS Res Hum Retroviruses 9 suppl 1 1993 S135
100. C. Lapham B. Golding J. Inman Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell depleted BALB/c mice J Virol 70 5 1996 3084
101. A. Lawler J. Cohen A deadline for an AIDS vaccine Science 276 1997 1184
102. N.L. Letvin Animal models for the study of human immunodeficiency virus infection Curr Opin Immunol 4 1992 481
103. J. Louwagie W. Janssens J. Mascola Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin J Virol 69 1995 263
104. J. Louwagie F.E. McCutchan M. Peeters Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes AIDS 7 1993 769
105. P. Lurie M. Bishaw M.A. Chesney Ethical, behavioural, and social aspects of HIV vaccine trials in developing countries JAMA 271 1994 295
106. S.J. Martin A. Vyakarnam R. Cheingsong-Popov Immunization of human HIV-seronegative volunteers with recombinant p17/p24: Ty virus-like particles elicit HIV-1 p24-specific cellular and humoral immune responses AIDS 7 1993 1315
107. P.A. Marx R.W. Compans A. Gettie Protection against vaginal SIV transmission with microencapsulated vaccine Science 260 1992 1323
108. M.J. McElrath L. Corey D. Berger Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting J Infect Dis 169 1994 41
109. M.J. McElrath L. Corey P. Greenberg Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen Proc Natl Acad Sci U S A 93 1997 3972
110. F. Miedema L. Meyaard M.R. Klein Protection from HIV infection or AIDS? Science 262 1993 1074
111. L. Montagnier J.C. Chermann F. Barre-Sinoussi Lymphadenopathy associated virus and its etiological role in AIDS Princess Takamatsu Symp 15 1984 319
112. D.M. Montefiori B.S. Graham J. Zhou V3 specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the confirmation-dependent CD4 binding site of gp120. NIH-NIAID AIDS vaccine clinical trials network J Clin Invest 92 1993 840
113. J.P. Moore F.E. McCutchan S.W. Poon Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies J Virol 68 1994 8350
114. C.D. Morrow D.C. Porter D.C. Ansardi New approaches for mucosal vaccines for AIDS: Encapsidation and serial passage of poliovirus replicons that express HIV-1 proteins on infection AIDS Res Human Retroviruses 10 suppl2 1994 S61
115. M. Murphey-Corb L.N. Martin B. Davison-Fairburn A formalin-inactivated whole SIV vaccine confers protection in macaques Science 246 1989 1293
116. G. Myers B.T.M. Korber R.F. Smith Human Retroviruses and AIDS 1993 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory Los Alamos
117. M.T. Niu D.S. Stein S.M. Schnittman Primary human immunodeficiency virus type 1 infection: Review of pathogenesis and early treatment intervention in humans and animal retrovirus infections J Infect Dis 168 1993 1490
118. R. Nowak Staging ethical AIDS trials in Africa Science 269 1995 1332
119. T.R. O'Brien J.J. Goedert Chemokine receptors and genetic variability, another leap in HIV research JAMA 279 1998 317
120. S. Osmanov W.L. Heyward J. Esparza The World Health Organization network for HIV isolation and characterization: Summary of a pilot study AIDS Res Hum Retroviruses 10 1994 1325
121. G. Pantaleo J.F. Demarest H. Soudeyns Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV Nature 370 1994 463
122. G. Pantaleo C. Graziosi L. Butini Lymphoid organs function as major reservoirs for human immunodeficiency virus Proc Natl Acad Sci U S A 88 1991 9838
123. G. Pantaleo C. Graziosi J.F. Demarest HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease Nature 362 1993 355
124. G. Pantaleo C. Graziosi A.S. Fauci The immunopathogenesis of human immunodeficiency virus infection N Engl J Med 328 1993 327
125. C.P. Pau M. Kai D.L. Holloman-Candal Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites AIDS Res Hum Retroviruses 10 1994 1369
126. W.E. Paul Reexamining AIDS research priorities Science 267 1995 633
127. Presidential Advisory Council on HIV and AIDS: AIDS vaccine panel discussion. 1–14, 1998
128. E. Raz D.A. Carson S.E. Parker Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses Proc Natl Acad Sci U S A 91 1994 9519
129. R.R. Redfield D.L. Birx N. Ketter A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection N Engl J Med 324 1991 1677
130. J.S. Robertson Safety considerations for nucleic acid vaccines Vaccine 12 1994 1526
131. J. Salk P.A. Bretscher P.L. Salk A strategy for prophylactic vaccines against HIV Science 260 1993 1270
132. A. Schultz S. Hu Primate models for HIV vaccines AIDS 7 suppl 1 1993 S161
133. P.M. Sharp D.L. Robertson F. Gao Origins and diversity of human immunodeficiency viruses AIDS 4 suppl 1 1994 S27
134. G.M. Shearer M. Clerici A. Dalgleish Alloimmunization as an AIDS vaccine? Science 262 1993 161
135. P.E. Stanhope M.L. Clements R.F. Siliciano Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit-vaccine J Infect Dis 168 1993 92
136. E. Stott Anti-cell antibody in macaques Nature 353 1991 393
137. E. Stott Towards a vaccine against AIDS: Lessons from simian immunodeficiency virus vaccines Curr Top Microbiol Immunol 188 1994 221
138. Tang S. van Rij R. D. Silvera Toward a poliovirus-based simian immunodeficiency virus vaccine: Correlation between genetic stability and immunogenicity J Virol 71 1997 7841
139. M. Thali U. Olshevsky C. Furman Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody J Virol 65 1991 6188
140. 3 CD4 T lymphocytes (AIDS clinical trials group protocol 137) J Infect Dis 173 1996 1336
141. van Akker R. M. Balls J.W. Eichberg Chimpanzees in AIDS research: A biomedical and bioethical perspective J Med Primatol 23 1994 49
142. H. Varmus Retroviruses Science 240 1988 1427
143. J. Veenstra I.G. Williams R. Colebunders Immunization with recombinant p17/24:Ty virus-like particles in human immunodeficiency virus-infected persons J Infect Dis 174 1996 862
144. S.H. Vermund R.D. Fischer R. Hoff Preparing for HIV vaccine efficacy trials: Partnerships and challenges AIDS Res Hum Retroviruses 9 suppl 1 1993 S127
145. R.J. Veugelers K.A. Page B. Tindall Determinants of HIV disease progression among homosexual men registered in the tricontinental seroconverter study Am J Epidemiol 140 1994 747
146. F.R. Vogel Role of adjuvants in HIV vaccine design Antibiot Chemother 48 1996 84
147. R. Wagner T. Boltz L. Deml Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses J Gen Virol 74 1993 1261
148. S. Wain-Hobson Immunodeficiency viruses Nature 391 1998 531
149. M. Walker P.E. Fast Clinical trials of experimental AIDS vaccines AIDS 8 suppl 1 1994 S213
150. B. Wang K.E. Ugen V. Srikantan Gene inoculation generates immune responses against human immunodeficiency virus type 1 Proc Natl Acad Sci U S A 90 1993 4156
151. C.Y. Wang D.J. Looney M.L. Li Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen Science 254 1991 285
152. J.T. Warren M. Dolatshahi Annual update survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates J Med Primatol 23 1994 184
153. X. Wei S.K. Ghosh M.E. Taylor Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117
154. WHO Network for HIV Isolation and Characterization HIV-type 1 variation in World Health Organization-sponsored vaccine evaluation sites: Genetic Screening, sequence analysis, and preliminary biological characterization of selected viral strains AIDS Res and Hum Retroviruses 10 1994 1327
155. gag protein: Understanding the mechanism of virus assembly as a basis for the development of novel therapeutics and vaccines. In Girard M, Valette L (eds): Retroviruses of Human AIDS and Related Animal Diseases, Colloques des Cent Gardes, 1993 Oct 25–27, Marnes-La-Coquette. Paris, Fondation Marcel Mearieux, 1994, p 299
156. World Health Organization The HIV/AIDS Pandemic. Overview 1993 Geneva World Health Organization
157. World Health Organization Working Group Feasibility of developing live attenuated HIV vaccines: Conclusions and recommendations AIDS Res Hum Retroviruses 10 1994 221
158. M.S. Wyand K.H. Manson M. Garcia-Moll Vaccine protection by a triple deletion mutant of simian immunodeficiency virus J Virol 70 1996 3724
159. Y. Yasutomi S. Koenig S.S. Haum Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys J Immunol 150 1993 310
160. Y. Yasutomi T.J. Palker M.B. Gardner Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys J Immunol 151 1993 5096
161. L. Zekeng L. Gurtler Afane Ze E. Prevalence of HIV-1 subtype O infection in Cameroon: Preliminary results AIDS 8 1994 1626
162. T. Zhu B.T. Korber A.J. Nahmias An African HIV-1 sequence from 1959 and implications for the origin of the epidemic Nature 391 1998 594